Painful chemotherapy-induced peripheral neuropathy: lack of treatment efficacy or the wrong clinical trial methodology?

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Pain

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/j.pain.0000000000000653PMID 27564867PMCID PMC6784316
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• National Cancer Institute-supported chemotherapy-induced peripheral neuropathy trials: outcomes and lessons

  2016cited by this paper
• Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.

  2014cited by this paper
• Mechanism-based treatment for chemotherapy-induced peripheral neuropathic pain

  2014cited by this paper
• A phase III randomized, placebo-controlled study of topical amitriptyline and ketamine for chemotherapy-induced peripheral neuropathy (CIPN): a University of Rochester CCOP study of 462 cancer survivors

  2014cited by this paper
• Assay sensitivity and study features in neuropathic pain trials

  2013cited by this paper
• Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial.

  2013influential reference
• Chemotherapy-induced peripheral neurotoxicity (CIPN): an update.

  2012cited by this paper
• Considerations for improving assay sensitivity in chronic pain clinical trials: IMMPACT recommendations

  2012cited by this paper
• A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA

  2011influential reference
• Recommendations for the pharmacological management of neuropathic pain: an overview and literature update.

  2010cited by this paper
• The evidence for pharmacological treatment of neuropathic pain

  2010cited by this paper
• Amitriptyline in the prevention of chemotherapy-induced neuropathic symptoms.

  2009cited by this paper
• Efficacy of lamotrigine in the management of chemotherapy‐induced peripheral neuropathy

  2008cited by this paper
• Amitriptyline in the treatment of chemotherapy-induced neuropathic symptoms.

  2008influential reference
• Efficacy of gabapentin in the management of chemotherapy‐induced peripheral neuropathy

  2007cited by this paper
• The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20.

  2005cited by this paper
• Core outcome measures for chronic pain clinical trials: IMMPACT recommendations

  2003cited by this paper
• Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group—Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy

  2003cited by this paper
• CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment.

  2003cited by this paper
• Phase III evaluation of nortriptyline for alleviation of symptoms of cis‐platinum‐induced peripheral neuropathy

  2002cited by this paper
• Toxicity and response criteria of the Eastern Cooperative Oncology Group

  1982cited by this paper

• The 3P‐CP model: Expanding our conceptualization of cancer pain

  2025cites this paper
• Topical Cannabidiol for Established Chemotherapy-Induced Neuropathy: A Pilot Randomized Placebo-Controlled Trial

  2024cites this paper
• Clinical pharmacology of neuropathic pain.

  2024cites this paper
• Mean of daily vs. single week recall-based pain quality assessments in neuropathic pain trials: Implications for assay sensitivity.

  2024cites this paper
• Neurological Complications of Conventional and Novel Anticancer Treatments

  2022cites this paper
• Assessing pain after cancer treatment

  2022cites this paper
• Endoplasmic Reticulum Stress in Chemotherapy-Induced Peripheral Neuropathy: Emerging Role of Phytochemicals

  2022cites this paper
• Efficacy and safety of electroacupuncture for oxaliplatin-induced peripheral neuropathy in colorectal cancer patients: a single-blinded, randomized, sham-controlled trial

  2022cites this paper
• Management of treatment‐related sequelae following colorectal cancer

  2022cites this paper
• Topical Cannabinoids for Treating Chemotherapy-Induced Neuropathy: A Case Series

  2021cites this paper
• TRPA1 involved in miR-141-5p-alleviated neuropathic pain induced by oxaliplatin.

  2021cites this paper
• Physiotherapy for people with painful peripheral neuropathies: a narrative review of its efficacy and safety

  2020cites this paper
• The efficacy and safety of electro-acupuncture for alleviating chemotherapy-induced peripheral neuropathy in patients with coloreactal cancer: study protocol for a single-blinded, randomized sham-controlled trial

  2020cites this paper
• Recent advances in understanding chemotherapy-induced peripheral neuropathy

  2020cites this paper
• Emerging pharmacological strategies for the management of chemotherapy-induced peripheral neurotoxicity (CIPN), based on novel CIPN mechanisms

  2020cites this paper
• The efficacy and safety of electro-acupuncture for alleviating chemotherapy-induced peripheral neuropathy in colorectal cancer patients: study protocol for a pilot single-blinded, randomized sham-controlled trial CURRENT

  2020cites this paper
• Estudio metaanalítico de la efectividad de los tratamientos farmacológicos y no farmacológicos en la neuropatía periférica inducida por quimioterapia

  2019cites this paper
• Psychometric Testing of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire–Chemotherapy-Induced Peripheral Neuropathy 20-Item Scale Using Pooled Chemotherapy-Induced Peripheral Neuropathy Outcome Measures Standardization and Alliance for Clinical Trials in O

  2019cites this paper
• Rational treatment of chemotherapy-induced peripheral neuropathy with capsaicin 8% patch: from pain relief towards disease modification

  2019cites this paper
• Characterization of Internal Validity Threats to Phase III Clinical Trials for Chemotherapy-Induced Peripheral Neuropathy Management: A Systematic Review

  2019influential citation
• Preliminary Effectiveness of Auricular Point Acupressure on Chemotherapy-Induced Neuropathy: Part 2 Laboratory-Assessed and Objective Outcomes.

  2019cites this paper
• Mechanisms, Predictors, and Challenges in Assessing and Managing Painful Chemotherapy-Induced Peripheral Neuropathy.

  2019cites this paper
• The Analgesic Effect of Venlafaxine and Its Mechanism on Oxaliplatin-Induced Neuropathic Pain in Mice

  2019cites this paper
• The efficacy and safety of acupuncture for alleviating chemotherapy-induced peripheral neuropathy in colorectal cancer patients: study protocol for a pilot single-blinded, randomized sham-controlled trial

  2019cites this paper
• In Search of a Gold Standard Patient-Reported Outcome Measure for Use in Chemotherapy- Induced Peripheral Neuropathy Clinical Trials

  2018cites this paper
• [Chemotherapy-induced peripheral neuropathy: Symptomatology and epidemiology].

  2018cites this paper
• Risk stratification of oxaliplatin induced peripheral neurotoxicity applying electrophysiological testing of dorsal sural nerve

  2018cites this paper
• Clinical assessment of new antineuropathic strategies for chemotherapy-induced peripheral neuropathy: pain should not be the principal endpoint.

  2017cites this paper
• Chemotherapy-induced peripheral neuropathy: a review of recent findings

  2017cites this paper